HHV-8 vIRF interactions in the context of infection

HHV-8 vIRF 在感染情况下的相互作用

基本信息

  • 批准号:
    8994365
  • 负责人:
  • 金额:
    $ 17.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-08-01 至 2017-07-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Human herpesvirus 8 (HHV-8) specifies four viral interferon regulatory factor homologues (vIRFs) that represent a novel set of virus-encoded proteins, so-far identified only in HHV-8 and closely related rhesus rhadinovirus. The HHV-8 vIRFs function to inhibit cellular IRF activities and other components of cellular defense pathways that promote cell cycle arrest and apoptosis in response to virus infection. Two of the vIRFs, vIRF-1 and vIRF-3, have been demonstrated to contribute significantly to either virus productive replication (in endothelial cells) or to latently infected cell viability [in primary efusion lymphoma (PEL) cells]; each vIRF is expressed during both latent (PEL) and lytic replication. Both phases of the virus life cycle are important for HHV-8 malignant pathogenesis: Kaposi's sarcoma, PEL, and multicentric Castleman's disease. Known targeted cellular proteins of vIRF-1 include IRFs, p300/CBP transcriptional co-activators required for IRF-mediated responses, IFN/retinoic acid-induced GRIM19, p53, p53-activating ATM kinase, and certain BH3-only (pro-apoptotic) members of the Bcl-2 family; vIRF-3 targets IRFs, p300/CBP, and p53. However, the full repertoire of inhibitory interactions of these pleiotropic proteins is far from clear and the interactions have not been adequately surveyed in the context of latent and lytic replication. Whilst we have determined that vIRF-1 interactions with BH3-only proteins are critical for successful productive replication in endothelial cells, the roles of other vIRF-1 interactions in lytic replication in these and other cells and the contributions of vIRF-1 and its interactions to PEL latency remain unknown. Similarly, the roles of vIRF-3 and its interactions in productive replication and of specific vIRF-3 interactions in latency remain to be determined. To address these issues, we propose to: (1) undertake affinity precipitations of vIRFs 1 and 3 from latently infected PEL and lytically infected PEL and endothelial cells followed by mass spectrometry analysis of co-precipitated cellular proteins; (2) use suppression, overexpression, and binding-competition analyses to identify the contributions of vIRFs 1 and 3, their cellular targets, and particular vIRF-protein interactions to latently infected cell viability and productive replication and to develop inhibitory agents. The project comprises a broadly-visioned but conceptually and experimentally focused analysis of unique viral innate immune evasion proteins whose functional and mechanistic contributions to virus biology are presently unclear. As these proteins are centrally important to both latency and productive replication, information generated from this study could provide the basis for development of novel antiviral and clinical therapies.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John Nicholas其他文献

John Nicholas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John Nicholas', 18)}}的其他基金

USP7 targeting by HHV-8 vIRFs
HHV-8 vIRF 靶向 USP7
  • 批准号:
    9883702
  • 财政年份:
    2019
  • 资助金额:
    $ 17.62万
  • 项目类别:
USP7 targeting by HHV-8 vIRFs
HHV-8 vIRF 靶向 USP7
  • 批准号:
    10361554
  • 财政年份:
    2019
  • 资助金额:
    $ 17.62万
  • 项目类别:
USP7 targeting by HHV-8 vIRFs
HHV-8 vIRF 靶向 USP7
  • 批准号:
    10581544
  • 财政年份:
    2019
  • 资助金额:
    $ 17.62万
  • 项目类别:
HHV-8 vIRF interactions in the context of infection
HHV-8 vIRF 在感染情况下的相互作用
  • 批准号:
    9085244
  • 财政年份:
    2015
  • 资助金额:
    $ 17.62万
  • 项目类别:
Inhibitory targeting of HHV-8 vIL-6-related interactions.
HHV-8 vIL-6 相关相互作用的抑制性靶向。
  • 批准号:
    8595304
  • 财政年份:
    2013
  • 资助金额:
    $ 17.62万
  • 项目类别:
BH3-only protein targeting by HHV-8
HHV-8 仅靶向 BH3 蛋白
  • 批准号:
    9193611
  • 财政年份:
    2013
  • 资助金额:
    $ 17.62万
  • 项目类别:
BH3-only protein targeting by HHV-8
HHV-8 仅靶向 BH3 蛋白
  • 批准号:
    8537068
  • 财政年份:
    2013
  • 资助金额:
    $ 17.62万
  • 项目类别:
Inhibitory targeting of HHV-8 vIL-6-related interactions.
HHV-8 vIL-6 相关相互作用的抑制性靶向。
  • 批准号:
    8467210
  • 财政年份:
    2013
  • 资助金额:
    $ 17.62万
  • 项目类别:
BH3-only protein targeting by HHV-8
HHV-8 仅靶向 BH3 蛋白
  • 批准号:
    8601429
  • 财政年份:
    2013
  • 资助金额:
    $ 17.62万
  • 项目类别:
BH3-only protein targeting by HHV-8
HHV-8 仅靶向 BH3 蛋白
  • 批准号:
    8786056
  • 财政年份:
    2013
  • 资助金额:
    $ 17.62万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 17.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 17.62万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 17.62万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 17.62万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 17.62万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 17.62万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 17.62万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 17.62万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 17.62万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 17.62万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了